SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults
Phase 4
Completed
- Conditions
- Influenza
- First Posted Date
- 2011-09-08
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 300
- Registration Number
- NCT01430819
A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: High Dose Trivalent Inactivated Influenza VaccineBiological: Trivalent Inactivated Influenza Vaccine
- First Posted Date
- 2011-09-01
- Last Posted Date
- 2015-04-20
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 31989
- Registration Number
- NCT01427309
Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers
Phase 3
Completed
- Conditions
- DengueDengue Hemorrhagic Fever
- Interventions
- Biological: Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virusBiological: DTaP IPV//Hib vaccineBiological: PlaceboBiological: Measles, mumps, and rubella vaccineBiological: Pneumococcal vaccine
- First Posted Date
- 2011-08-08
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 720
- Registration Number
- NCT01411241
Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers
Phase 3
Completed
- Conditions
- Japanese EncephalitisJapanese Encephalitis Virus Disease
- Interventions
- Biological: Live attenuated Japanese encephalitis chimeric virus vaccineBiological: Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2014-04-25
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 274
- Registration Number
- NCT01396512
Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan
Phase 3
Completed
- Conditions
- PoliomyelitisPolio
- Interventions
- Biological: Inactive Poliovirus Vaccine
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2013-03-29
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 74
- Registration Number
- NCT01389687
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America
Phase 3
Completed
- Conditions
- Dengue Hemorrhagic FeverDengueDengue Fever
- Interventions
- Biological: Live, attenuated, dengue serotype 1, 2, 3, 4 virus
- First Posted Date
- 2011-06-16
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 20869
- Registration Number
- NCT01374516
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia
Phase 3
Completed
- Conditions
- DengueDengue FeverDengue Hemorrhagic Fever
- Interventions
- Biological: Live, attenuated, dengue serotype 1, 2, 3, 4 virus
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 10275
- Registration Number
- NCT01373281
Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations
Phase 3
Completed
- Conditions
- Meningococcal InfectionMeningitis
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2016-08-19
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 123
- Registration Number
- NCT01359449
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Phase 3
Completed
- Conditions
- TetanusDiphtheriaMeaslesPertussisPolio
- Interventions
- Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella VirusBiological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus
- First Posted Date
- 2011-05-02
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 3372
- Registration Number
- NCT01346293
Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine
Phase 3
Completed
- Conditions
- RabiesRabies Virus
- Interventions
- Biological: Purified inactivated rabies vaccine, serum freeBiological: Purified Vero Rabies Vaccine
- First Posted Date
- 2011-04-20
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 816
- Registration Number
- NCT01339312
© Copyright 2025. All Rights Reserved by MedPath